Pascal Finetti
Overview
Explore the profile of Pascal Finetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
191
Citations
6426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Udu-Ituma S, Adelaide J, Le T, Omabe K, Finetti P, Paris C, et al.
Pharmaceutics
. 2023 Jul;
15(7).
PMID: 37514116
The luminal B molecular subtype of breast cancers (BC) accounts for more than a third of BCs and is associated with aggressive clinical behavior and poor prognosis. The use of...
12.
Bertucci F, Finetti P, Mamessier E, de Nonneville A
Cancer Commun (Lond)
. 2023 Jul;
43(8):938-942.
PMID: 37462449
No abstract available.
13.
Nigon E, Lefeuvre-Plesse C, Martinez A, Chauleur C, Lortholary A, Favier L, et al.
J Transl Med
. 2023 Jun;
21(1):408.
PMID: 37353806
Background: Uterine clear cell carcinomas (CCC) represent less than 5% of uterine cancers. Their biological characteristics and clinical management remain uncertain. A multicenter study to explore both clinical and molecular...
14.
Bertucci F, de Nonneville A, Finetti P, Mamessier E
Cancer Commun (Lond)
. 2023 Jun;
43(8):943-946.
PMID: 37278484
No abstract available.
15.
Miallot R, Millet V, Groult Y, Modelska A, Crescence L, Roulland S, et al.
Life Sci Alliance
. 2023 Apr;
6(6).
PMID: 37024121
Aggressive tumors often display mitochondrial dysfunction. Upon oxidative stress, mitochondria undergo fission through OMA1-mediated cleavage of the fusion effector OPA1. In yeast, a redox-sensing switch participates in OMA1 activation. 3D...
16.
Bertucci F, de Nonneville A, Finetti P, Mamessier E
J Natl Cancer Inst
. 2023 Apr;
115(6):762-763.
PMID: 37004188
No abstract available.
17.
de Nonneville A, Finetti P, Boudin L, Denicolai E, Birnbaum D, Mamessier E, et al.
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986799
Background: LIV1 is a transmembrane protein that may become a new therapeutic target through the development of antibody-drug conjugates (ADCs). Few studies are available regarding the assessment of expression in...
18.
Rapetti-Mauss R, Nigri J, Berenguier C, Finetti P, Tubiana S, Labrum B, et al.
Gut
. 2023 Mar;
72(4):722-735.
PMID: 36882214
Objective: Intercellular communication within pancreatic ductal adenocarcinoma (PDAC) dramatically contributes to metastatic processes. The underlying mechanisms are poorly understood, resulting in a lack of targeted therapy to counteract stromal-induced cancer...
19.
Bigarre C, Bertucci F, Finetti P, MacGrogan G, Muracciole X, Benzekry S
Comput Methods Programs Biomed
. 2023 Feb;
231:107401.
PMID: 36804267
Background And Objective: Estimating the risk of metastatic relapse is a major challenge to decide adjuvant treatment options in early-stage breast cancer (eBC). To date, distant metastasis-free survival (DMFS) analysis...
20.
Birnbaum D, Picard M, Da Costa Q, Delayre T, Finetti P, Cabaud O, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672396
Hepatocellular carcinoma (HCC) is a frequent and deadly cancer in need of new treatments. Immunotherapy has shown promising results in several solid tumors. The TIGIT/DNAM-1 axis gathers targets for new...